At the news
? BEARISHIMPACT 7/10 8-K filed Jun 24, 2026 at 16:15 ET
Passage Bio entered into a definitive all-stock merger agreement with Remix Therapeutics, where pre-merger Passage shareholders will own only ~7% of the combined company. The deal is supported by an oversubscribed $100M+ PIPE led by Decheng Capital, funding the combined entity into 2028 to advance Remix's lead oral MYB mRNA degrader REM-422. Passage shareholders also receive contingent value rights tied to legacy gene therapy milestones, but the massive dilution and effective change of control make this a highly negative event for current PASG holders.
- Passage Bio shareholders will own approximately 7% of the combined company post-merger, with Remix shareholders (including PIPE investors) owning ~93%
- Concurrent PIPE of $69,999,999.28 plus convertible notes totaling at least $99,929,000 in gross proceeds
- Remix Equity Value set at $226M, Passage Equity Value at $20M in the merger exchange ratio
- Passage will change its name to Remix Therapeutics, Inc. and board/management will be replaced by Remix designees
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access